Conference abstract · 5 Dec 2016
Conference abstractPublished 5 Dec 2016
Glycopeptide drugs
University of Arizona, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
ParkinsonâÂ?Â?s disease (PD) is the 2nd most common neurodegenerative disorder, affecting over 1 million people in the US. ParkinsonâÂ?Â?s disease causes difficulties with movements such as walking, writing and speaking that occur because of deficiencies of the chemical dopamine in the brain. Current therapies for PD only treat the symptoms and do not reverse underlying disease processes that cause dopamine-producing brain cells to die. This situation has led to widespread interest in new strategies of neuroprotection or neurorestoration. The mostpromising approaches to modifying the disease process in the laboratory have relied on natural brain chemicals known as âÂ?Â?growth factorsâÂ?. Several growth factors have demonstrated the ability to reverse the disease process in animal models of PD. A few of these growth factors have shown sufficient promise that they have been tested in clinical trials in humans with PD. One promising approach is offered by the peptide âÂ?Â?secretinsâÂ? vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) which plays important roles in neuronal survival, neuroprotection, inflammation and immunomodulation. PACAP seems to be protective against the loss of dopamine-producing brain cells in rodent model of ParkinsonâÂ?Â?s, but only after being injected directly into the brain. The proposed glycopeptides are surfactants, chemically speaking, and have extended half-lives in vivo and unlike their peptide counterparts, these molecules can efficiently cross the blood-brain barrier (BBB). We have developed a new technology platform to develop glycopeptide analogues that show increased stability. We will synthesize a series of novel glycopeptides based on PACAP and VIP to screen their efficacy at PAC1, VPAC1 and VPAC2 receptors expressed in CHO reporter cells and test the most promising compounds in animal models of ParkinsonâÂ?Â?s disease. We will be assisted greatly in this endeavor by micro-dialysis data that will allow us to quantify brain levels of the drug over time, and direct measurements of drug stability in vivo. This is accomplished by multiple collision-induced fragmentation mass spectroscopy (MSn). In this way we hope to produce one or more drug candidates for further study, ultimately leading to clinical application.
Subjects
ChemistryPharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 29 Aug 2016
Glycans in drug design: Glycopeptide drugs from endogenous neuropeptides
Research article · 2014
Design, Synthesis, and Evaluation of Glycopeptides Containing Glucosamine
Commentary · 13 Jun 2023
Presentation of the Potential of Glycopeptides: A Unique Class of Antibiotics in the Fight against Antibiotic Resistance
Conference abstract · 2018
Glycopeptides by quantum chemistry and artificial intelligence
More from this journal
The newest in Medicinal Chemistry.
Brief report · 30 Jun 2026
Covalent Drugs in Medicinal Chemistry: Emerging Opportunities and Ongoing Challenges
Commentary · 29 Dec 2025
Accelerating Drug Discovery: Molecular Docking and Virtual Screening
Opinion · 29 Dec 2025
Pharmacophore Modeling: A Cornerstone of Drug Discovery
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMedicinal Chemistry
- SubjectChemistry
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Robin Polt”

